Progress on plague vaccine development

Jason A. Rosenzweig, Olufisayo Jejelowo, Jian Sha, Tatiana E. Erova, Sheri M. Brackman, Michelle L. Kirtley, Cristina J. Van Lier, Ashok Chopra

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Yersinia pestis (YP), the gram-negative plague bacterium, has shaped human history unlike any other pathogen known to mankind. YP (transmitted by the bite of an infected flea) diverged only recently from the related enteric pathogen Yersinia pseudotuberculosis but causes radically different diseases. Three forms of plague exist in humans: bubonic (swollen lymph nodes or bubos), septicemic (spread of YP through the lymphatics or bloodstream from the bubos to other organs), and contagious, pneumonic plague which can be communicated via YP-charged respiratory droplets resulting in person-person transmission and rapid death if left untreated (50-90% mortality). Despite the potential threat of weaponized YP being employed in bioterrorism and YP infections remaining prevalent in endemic regions of the world where rodent populations are high (including the four corner regions of the USA), an efficacious vaccine that confers immunoprotection has yet to be developed. This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor.

Original languageEnglish (US)
Pages (from-to)265-286
Number of pages22
JournalApplied Microbiology and Biotechnology
Volume91
Issue number2
DOIs
StatePublished - Jul 2011

Fingerprint

Plague Vaccine
Yersinia pestis
Plague
Vaccines
Yersinia Infections
Yersinia pseudotuberculosis
Bioterrorism
Siphonaptera
Bites and Stings
Gram-Negative Bacteria
Rodentia
Lymph Nodes
History
Mortality

Keywords

  • Bubonic
  • Plague
  • Pneumonic plague
  • Septicemic
  • Vaccine
  • Yersinia pestis

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Rosenzweig, J. A., Jejelowo, O., Sha, J., Erova, T. E., Brackman, S. M., Kirtley, M. L., ... Chopra, A. (2011). Progress on plague vaccine development. Applied Microbiology and Biotechnology, 91(2), 265-286. https://doi.org/10.1007/s00253-011-3380-6

Progress on plague vaccine development. / Rosenzweig, Jason A.; Jejelowo, Olufisayo; Sha, Jian; Erova, Tatiana E.; Brackman, Sheri M.; Kirtley, Michelle L.; Van Lier, Cristina J.; Chopra, Ashok.

In: Applied Microbiology and Biotechnology, Vol. 91, No. 2, 07.2011, p. 265-286.

Research output: Contribution to journalArticle

Rosenzweig, JA, Jejelowo, O, Sha, J, Erova, TE, Brackman, SM, Kirtley, ML, Van Lier, CJ & Chopra, A 2011, 'Progress on plague vaccine development', Applied Microbiology and Biotechnology, vol. 91, no. 2, pp. 265-286. https://doi.org/10.1007/s00253-011-3380-6
Rosenzweig JA, Jejelowo O, Sha J, Erova TE, Brackman SM, Kirtley ML et al. Progress on plague vaccine development. Applied Microbiology and Biotechnology. 2011 Jul;91(2):265-286. https://doi.org/10.1007/s00253-011-3380-6
Rosenzweig, Jason A. ; Jejelowo, Olufisayo ; Sha, Jian ; Erova, Tatiana E. ; Brackman, Sheri M. ; Kirtley, Michelle L. ; Van Lier, Cristina J. ; Chopra, Ashok. / Progress on plague vaccine development. In: Applied Microbiology and Biotechnology. 2011 ; Vol. 91, No. 2. pp. 265-286.
@article{b7bca5fbbf04489dabeb439d6f9504c7,
title = "Progress on plague vaccine development",
abstract = "Yersinia pestis (YP), the gram-negative plague bacterium, has shaped human history unlike any other pathogen known to mankind. YP (transmitted by the bite of an infected flea) diverged only recently from the related enteric pathogen Yersinia pseudotuberculosis but causes radically different diseases. Three forms of plague exist in humans: bubonic (swollen lymph nodes or bubos), septicemic (spread of YP through the lymphatics or bloodstream from the bubos to other organs), and contagious, pneumonic plague which can be communicated via YP-charged respiratory droplets resulting in person-person transmission and rapid death if left untreated (50-90{\%} mortality). Despite the potential threat of weaponized YP being employed in bioterrorism and YP infections remaining prevalent in endemic regions of the world where rodent populations are high (including the four corner regions of the USA), an efficacious vaccine that confers immunoprotection has yet to be developed. This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor.",
keywords = "Bubonic, Plague, Pneumonic plague, Septicemic, Vaccine, Yersinia pestis",
author = "Rosenzweig, {Jason A.} and Olufisayo Jejelowo and Jian Sha and Erova, {Tatiana E.} and Brackman, {Sheri M.} and Kirtley, {Michelle L.} and {Van Lier}, {Cristina J.} and Ashok Chopra",
year = "2011",
month = "7",
doi = "10.1007/s00253-011-3380-6",
language = "English (US)",
volume = "91",
pages = "265--286",
journal = "Applied Microbiology and Biotechnology",
issn = "0175-7598",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Progress on plague vaccine development

AU - Rosenzweig, Jason A.

AU - Jejelowo, Olufisayo

AU - Sha, Jian

AU - Erova, Tatiana E.

AU - Brackman, Sheri M.

AU - Kirtley, Michelle L.

AU - Van Lier, Cristina J.

AU - Chopra, Ashok

PY - 2011/7

Y1 - 2011/7

N2 - Yersinia pestis (YP), the gram-negative plague bacterium, has shaped human history unlike any other pathogen known to mankind. YP (transmitted by the bite of an infected flea) diverged only recently from the related enteric pathogen Yersinia pseudotuberculosis but causes radically different diseases. Three forms of plague exist in humans: bubonic (swollen lymph nodes or bubos), septicemic (spread of YP through the lymphatics or bloodstream from the bubos to other organs), and contagious, pneumonic plague which can be communicated via YP-charged respiratory droplets resulting in person-person transmission and rapid death if left untreated (50-90% mortality). Despite the potential threat of weaponized YP being employed in bioterrorism and YP infections remaining prevalent in endemic regions of the world where rodent populations are high (including the four corner regions of the USA), an efficacious vaccine that confers immunoprotection has yet to be developed. This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor.

AB - Yersinia pestis (YP), the gram-negative plague bacterium, has shaped human history unlike any other pathogen known to mankind. YP (transmitted by the bite of an infected flea) diverged only recently from the related enteric pathogen Yersinia pseudotuberculosis but causes radically different diseases. Three forms of plague exist in humans: bubonic (swollen lymph nodes or bubos), septicemic (spread of YP through the lymphatics or bloodstream from the bubos to other organs), and contagious, pneumonic plague which can be communicated via YP-charged respiratory droplets resulting in person-person transmission and rapid death if left untreated (50-90% mortality). Despite the potential threat of weaponized YP being employed in bioterrorism and YP infections remaining prevalent in endemic regions of the world where rodent populations are high (including the four corner regions of the USA), an efficacious vaccine that confers immunoprotection has yet to be developed. This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor.

KW - Bubonic

KW - Plague

KW - Pneumonic plague

KW - Septicemic

KW - Vaccine

KW - Yersinia pestis

UR - http://www.scopus.com/inward/record.url?scp=79960740080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960740080&partnerID=8YFLogxK

U2 - 10.1007/s00253-011-3380-6

DO - 10.1007/s00253-011-3380-6

M3 - Article

VL - 91

SP - 265

EP - 286

JO - Applied Microbiology and Biotechnology

JF - Applied Microbiology and Biotechnology

SN - 0175-7598

IS - 2

ER -